Association between dapagliflozin use and coronary collateral circulation in patients with type 2 diabetes: A hypothesis-generating study


KÖKER G., ŞAHİNTÜRK Y., COŞKUNER M. A., Koc L. Z., Kumas F. H., Zorlu Gorgulugil G., ...Daha Fazla

Journal of Investigative Medicine, cilt.74, sa.5, ss.458-467, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 74 Sayı: 5
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1177/10815589251382270
  • Dergi Adı: Journal of Investigative Medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, MEDLINE, Social Science Premium Collection (ProQuest), Criminology Collection (ProQuest), Health Research Premium Collection (ProQuest)
  • Sayfa Sayıları: ss.458-467
  • Anahtar Kelimeler: type 2 diabetes mellitus, coronary artery disease, coronary collateral circulation, SGLT2 inhibitors, dapagliflozin
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Coronary collateral circulation (CCC) plays a vital compensatory role in patients with type 2 diabetes mellitus (T2DM) and obstructive coronary artery disease (CAD). However, impaired collateral development is common in T2DM, and therapeutic strategies to enhance CCC are underexplored. We aimed to evaluate the association between sodium-glucose cotransporter-2 inhibitor dapagliflozin use and coronary collateral development in T2DM patients with obstructive CAD. This cross-sectional study evaluated 59 T2DM patients undergoing coronary angiography for total coronary occlusion. CCC was graded using the Rentrop classification, and patients were divided into poor and good CCC groups. Propensity score matching (PSM) and multivariate logistic regression analyses were performed to identify independent predictors of good CCC. Good CCC was observed in 74.6% of patients. Dapagliflozin use was significantly more common among patients with good CCC (81.8% vs 13.3%, p < 0.001). In multivariate analysis, dapagliflozin use was significantly associated with good CCC (odds ratio: 32.5; 95% confidence interval (CI): 5.21–642, p = 0.002). After PSM, the dapagliflozin use remained a significant predictor. ROC analysis demonstrated strong discriminative ability (AUC: 0.821; 95% CI: 0.711–0.932). Dapagliflozin use is likely associated with enhanced coronary collateral development in T2DM patients with obstructive CAD, indicating a possible mechanism underlying its cardioprotective effects beyond glycemic control.